Healthcare
•3759 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3759)
| Company | Market Cap | Price |
|---|---|---|
|
AKTX
Akari Therapeutics, Plc
Core product category: antibody-drug conjugates (ADC) platform and lead AKTX-101 using PH1 payload targeting Trop2.
|
$22.08M |
$0.46
+3.45%
|
|
NAII
Natural Alternatives International, Inc.
Direct contract manufacturing services for private-label vitamins, minerals, herbal and other health care products.
|
$21.99M |
$3.64
|
|
GDTC
CytoMed Therapeutics Limited
Core business platform focuses on cell-based immunotherapies (gamma delta T cells, NK cells), aligning with Biotech - Cell Therapy.
|
$21.93M |
$1.88
-1.05%
|
|
MODD
Modular Medical, Inc.
MODD directly manufactures insulin pumps (MODD1 and Pivot), a core medical device product category categorized under Medical Devices & Biometrics.
|
$21.71M |
$0.41
+2.80%
|
|
BMGL
Basel Medical Group Ltd Ordinary Shares
BMGL provides hospital-style healthcare services, including inpatient/outpatient care via clinics and integrated care delivery.
|
$21.68M |
$1.17
+0.43%
|
|
ITRM
Iterum Therapeutics plc
ORLYNVAH is an oral small molecule antibiotic (sulopenem) that the company is launching commercially.
|
$20.95M |
$0.47
+7.51%
|
|
GTHP
Guided Therapeutics, Inc.
LuViva is a point-of-care diagnostic device used for cervical cancer screening, which aligns with Diagnostic Equipment.
|
$20.90M |
$0.25
|
|
AYTU
Aytu BioPharma, Inc.
AYTU's core ADHD portfolio comprises oral small-molecule therapeutics (Adzenys XR-ODT, Cotempla XR-ODT) and Karbinal ER, fitting the 'Oral Small Molecule Therapeutics' category.
|
$20.82M |
$2.13
+0.71%
|
|
BEAT
HeartBeam, Inc.
Direct diagnostic equipment derived from HeartBeam's synthesized 12-lead ECG device.
|
$20.71M |
$0.60
+3.62%
|
|
PALI
Palisade Bio, Inc.
PALI-2108 is an orally administered small molecule therapeutic, matching the Oral Small Molecule Therapeutics tag.
|
$20.34M |
$2.22
+3.26%
|
|
KPEA
Kun Peng International Ltd.
The business includes health care equipment-based services and devices, aligning with medical devices & equipment.
|
$20.00M |
$0.05
|
|
ENLV
Enlivex Therapeutics Ltd.
Allocetra is Enlivex's lead cell therapy platform, directly produced and administered as a therapeutic cell product.
|
$19.79M |
$0.91
-7.55%
|
|
LEXX
Lexaria Bioscience Corp.
Lexaria's DehydraTECH is a proprietary drug delivery platform that enhances API absorption and enables oral formulations.
|
$19.67M |
$1.12
+3.70%
|
|
SYBX
Synlogic, Inc.
PKU is a rare metabolic disease and Synlogic's lead programs target rare diseases via a synthetic biology platform.
|
$19.30M |
$1.69
+1.20%
|
|
LIXT
Lixte Biotechnology Holdings, Inc.
LB-100 is Lixte's lead oncology drug candidate (PP2A inhibitor) being developed for cancer therapy, constituting the primary product/offerable asset.
|
$19.20M |
$4.24
+3.67%
|
|
CVKD
Cadrenal Therapeutics, Inc. Common Stock
Cadrenal's tecarfarin is described as a novel oral small-molecule therapeutic, directly aligning with the 'Oral Small Molecule Therapeutics' tag.
|
$19.20M |
$9.69
-2.32%
|
|
COSM
Cosmos Health Inc.
Owns/operates in-house EU GMP manufacturing via Cana Laboratories Holdings Cyprus Ltd. and Cana S.A., enabling contract manufacturing revenue.
|
$19.14M |
$0.63
+0.70%
|
|
NSYS
Nortech Systems Incorporated
Medical Device Components manufacturing and assembly for regulated markets.
|
$18.97M |
$7.14
+2.73%
|
|
NXL
Nexalin Technology, Inc.
Core product is non-invasive neuromodulation devices for brain stimulation (Gen-2 SYNC, Gen-3 HALO).
|
$18.81M |
$1.09
+3.30%
|
|
INTS
Intensity Therapeutics, Inc.
Company develops oncology-focused therapeutics (INT230-6.00) and operates in Biotech - Oncology.
|
$18.65M |
$0.40
+1.34%
|
|
ALLR
Allarity Therapeutics, Inc.
Allarity is a clinical-stage biotech focused on oncology therapies (stenoparib) and cancer drug development.
|
$18.27M |
$1.26
+7.20%
|
|
PYPD
PolyPid Ltd.
D-PLEX100 leverages PolyPid's PLEX drug-delivery platform to provide localized, prolonged antibiotic release at the surgical site.
|
$18.23M |
$3.77
+2.45%
|
|
TRAW
Traws Pharma, Inc.
Company is developing Antiviral Small-Molecule Therapeutics (ratutrelvir) for COVID-19 as a core antiviral program.
|
$18.08M |
$2.57
-2.28%
|
|
LSTA
Lisata Therapeutics, Inc.
Certepetide is a proprietary peptide therapeutic, fitting Peptide Therapeutics.
|
$17.95M |
$2.06
-0.24%
|
|
ATHA
Athira Pharma, Inc.
ATH-1105 is described as an orally available, brain-penetrant small molecule developed for ALS, fitting the 'Oral Small Molecule Therapeutics' tag.
|
$17.83M |
$4.77
+6.24%
|
|
LPCN
Lipocine Inc.
Lipocine leverages the proprietary Lipral drug delivery platform, a core asset that enables oral delivery of challenging molecules and underpins its product candidates.
|
$17.77M |
$3.33
+1.83%
|
|
COCH
Envoy Medical, Inc.
Envoy Medical designs and manufactures implantable medical devices with biometric sensing capabilities (Acclaim CI and Esteem FI-AMEI).
|
$17.19M |
$0.80
-0.05%
|
|
EVOK
Evoke Pharma, Inc.
Gimoti relies on a nasal drug-delivery platform/technology, making Drug Delivery Platforms a core investable theme for Evoke's product strategy.
|
$16.89M |
$10.86
+0.51%
|
|
APLM
Apollomics, Inc.
The company is a biotechnology oncology-focused firm actively developing cancer therapies (vebreltinib and apolecylin) with multiple clinical programs.
|
$16.76M |
$17.14
+6.20%
|
|
TOMZ
TOMI Environmental Solutions, Inc.
Product category aligns with healthcare-themed medical devices and equipment, including disinfection hardware (SteraMist SIS/CES).
|
$16.66M |
$0.85
+4.81%
|
|
PETV
PetVivo Holdings, Inc.
PetVivo's Spryng is a veterinarian-administered medical device/biomaterial for osteoarthritis in dogs and horses.
|
$16.64M |
$1.08
|
|
PULM
Pulmatrix, Inc.
Pulmatrix's core offering is the iSPERSE dry powder drug delivery platform, a direct product category.
|
$16.40M |
$4.54
+5.21%
|
|
NXPL
NextPlat Corp
Management is pivoting toward higher-margin healthcare services and 340B contracts, a Healthcare Services & Facilities focus.
|
$16.15M |
$0.63
+0.10%
|
|
IRIX
IRIDEX Corporation
IRIDEX directly designs, manufactures and sells ophthalmology devices (laser platforms, delivery systems) for eye diseases.
|
$16.14M |
$0.96
+3.80%
|
|
KNW
Know Labs, Inc.
Core product: KnowU CGM wearable and glucose monitoring device.
|
$16.05M |
$2.14
|
|
RBOT
Vicarious Surgical Inc.
The company directly manufactures and sells surgical equipment in a robotic system for minimally invasive surgery.
|
$16.01M |
$2.71
+8.84%
|
|
HOTH
Hoth Therapeutics, Inc.
HT-001 (oncology supportive care) and HT-KIT/HT-ALZ pipelines place Hoth in oncology/biotech with a focused cancer therapy strategy.
|
$15.91M |
$1.21
+3.42%
|
|
MRKR
Marker Therapeutics, Inc.
Marker Therapeutics develops MAR-T cell therapies, a cell-based immunotherapy platform targeting cancer.
|
$15.79M |
$1.24
+12.73%
|
Showing page 32 of 38 (3759 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
